Treats major depressive disorder (MDD). Sold as Desvenlafaxine, Khedezla. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 15, 2026, FDA lists 3 applications for Desvenlafaxine (sold as Desvenlafaxine, Khedezla), first approved Mar 4, 2013, with 0 new uses approved and 0 published complete response letters.
| Desvenlafaxine Succinate ER | Part D | $66.1M | +9% | 203,933 |
| Pristiq | Part D | $5.7M | -7% | 1,308 |
| Desvenlafaxine ER | Part D | $2.2M | -1% | 4,214 |
| Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPainful Diabetic Neuropathy (PDN), Diabetic Nephropathies · University of Michigan | Phase 4 | Not yet recruiting | Aug 31, 2026 |
| Desvenlafaxine for Preventive Treatment of Frequent MigrainesMigraine · Tongji Hospital | Not applicable | Active, not recruiting | Feb 4, 2026 |
| The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes ZosterHerpes Zoster, Pain · Beijing Tiantan Hospital | Not applicable | Recruiting | Jan 23, 2026 |
| Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type HeadacheTension Type Headache · Tongji Hospital | Not applicable | Active, not recruiting | Jan 22, 2026 |
| The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With FibromyalgiaFibromyalgia, Pregabalin · Beijing Tiantan Hospital | Not applicable | Recruiting | Sep 12, 2025 |
| Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life DepressionDepression · University of Illinois Chicago | Phase 2 | Recruiting | Sep 19, 2024 |
| Implementation of Personalized Medicine for Optimal Drug Therapy in CancerNausea With Vomiting Chemotherapy-Induced, Depression, Reactive · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — | Recruiting | Apr 26, 2023 |
| Predictors of Cognitive Outcomes in Geriatric DepressionMajor Depressive Disorder, Neuroticism · David Steffens | Phase 4 | Active, not recruiting | Mar 10, 2022 |
| Mar 4, 2013 | DesvenlafaxineNDA 204150 · New formulation or manufacturer | Alembic Pharms Ltd | 9 | Marketed |
| Jul 10, 2013 | KhedezlaNDA 204683 · New formulation or manufacturer | Osmotica Pharm Corp | 7 | Discontinued |
| — | DesvenlafaxineANDA 204009 | Anchen Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
